11/14
09:15 am
pmn
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Low
Report
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
11/12
07:28 am
pmn
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference [Canadian Business Journal (Canada)]
Medium
Report
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference [Canadian Business Journal (Canada)]
11/12
07:00 am
pmn
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Medium
Report
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
10/30
08:09 am
pmn
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference [Financial Post (Toronto, Ontario, Canada)]
10/30
08:00 am
pmn
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Low
Report
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
10/13
03:00 pm
pmn
ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now [Yahoo! Finance]
Low
Report
ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now [Yahoo! Finance]
9/12
07:09 am
pmn
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences [Financial Post (Toronto, Ont
Medium
Report
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences [Financial Post (Toronto, Ont
9/12
07:00 am
pmn
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
Medium
Report
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
9/5
07:00 am
pmn
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
High
Report
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference